/ /

Ophthalmology

5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
Better diagnosis, treatment options key to nonresponsive bacterial keratitisNew treatment possibilities for nonresponsive bacterial keratitis are continually in development, including molecular-targeted therapy, the cautious use of topical corticosteroids, corneal crosslinking for superficial keratitis, and biologicals, Eduardo C. Alfonso, MD, reported.
Natamycin still the best bet for fungal keratitisA recent study sponsored by the National Eye Institute (NEI) of the optimal treatments for fungal keratitis showed that topical natamycin is still the mainstay of treatment. Adding oral voriconazole to the treatment regimen also may be beneficial to treat patients with Fusarium species.
The underlying, big hairy goal of eye careHow long does it actually take to form a new habit? Is there any science to back this up? And what does all of this mean for your practice?
Intracanalicular insert soothes ocular itching in allergic conjunctivitisA phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.
Ocular surface tumors require careful exam, consideration of best options
Ocular surface tumors require careful exam, consideration of best optionsAlthough surgery is still the gold standard for ocular surface tumors, consider the pros and cons of topical chemotherapy as appropriate.
New pathways to cancer therapyA novel oral formulation of itraconazole (SUBA-Itraconazole, HedgePath Pharmaceuticals) is providing dramatic benefit for patients with basal cell carcinoma nevus syndrome (BCCNS, also known as Gorlin syndrome) and with a favorable safety profile, according to a recent interim analysis of data collected in a phase IIb study.
A wake-up call for physiciansEveryone knows the name of Warren Buffett, the famous octogenarian-billionaire businessman and investor. His folksy persona and investment insights/elevated returns have earned him the appellation of “The Oracle of Omaha.” His estimated net worth of more than $74 billion makes him one of the wealthiest people on the planet.
Quantifying ectasia risk after LASIKA preliminary analysis of a dataset containing more than 300,000 eyes treated with LASIK between 6 to 10 years ago is beginning to quantify some of the risks for ectasia.